Recruiting studies: Acute Myeloid Leukemia With Kmt2A Rearrangement

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555 A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184 SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren
Phase 1 · 4 location(s) · Uma Borate · NCT06222580 Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07537738 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patien
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT05886049 A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1/Phase 2 · 57 location(s) · Syndax Pharmaceuticals · NCT04065399 Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Maligna
Phase 1/Phase 2 · 30 location(s) · AstraZeneca · NCT07155226 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 45 location(s) · Kura Oncology, Inc. · NCT06001788

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.